Dataset from A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009371
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC)
daratumumab administered in combination with standard multiple myeloma (MM) regimens in
participants with MM as measured by overall response rate (ORR) or very good partial response
(VGPR) or better rate.
创建时间：
2024-11-26
